Simak Ali
YOU?
Author Swipe
View article: Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells
Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells Open
View article: Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer.
Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer. Open
Triple-negative breast cancer (TNBC) is a highly invasive breast cancer subtype that is challenging to treat due to inherent heterogeneity and absence of estrogen, progesterone, and human epidermal growth factor 2 receptors. Kinase signali…
View article: TRIM24 as a therapeutic target in endocrine treatment–resistant breast cancer
TRIM24 as a therapeutic target in endocrine treatment–resistant breast cancer Open
While Estrogen receptor alpha (ERα)+ breast cancer treatment is considered effective, resistance to endocrine therapy is common. Since ERα is still the main driver in most therapy-resistant tumors, alternative therapeutic strategies are ne…
View article: Distinct 2-phenyl-imidazo[1, 2α] pyridine derivatives drive ER degradation and selectively impair proliferation of ER<sup>+</sup> breast cancer cells via the aryl hydrocarbon receptor
Distinct 2-phenyl-imidazo[1, 2α] pyridine derivatives drive ER degradation and selectively impair proliferation of ER<sup>+</sup> breast cancer cells via the aryl hydrocarbon receptor Open
X15695 is a 2-phenyl-imidazo[1, 2α] pyridine derivative identified as an orally active, selective oestrogen receptor (ER) degrader that inhibits the proliferation of ER + breast cancer cells. Here, we show that X15695 is an aryl hydrocarbo…
View article: Modulation of Estrogen Receptor Activity by the Phytoalexin Tuberosin Produced from Elicited Kudzu (<i>Pueraria lobata</i>)
Modulation of Estrogen Receptor Activity by the Phytoalexin Tuberosin Produced from Elicited Kudzu (<i>Pueraria lobata</i>) Open
Kudzu's invasive nature has contributed to its classification as a weed, as it frequently outcompetes native plant species, leading to extensive overgrowth. Efforts to control kudzu have proven challenging, with moderate success using phys…
View article: Long-term activation of mast cells as an experimental model for studying their role in the regulation of spermatogenesis
Long-term activation of mast cells as an experimental model for studying their role in the regulation of spermatogenesis Open
Mast cells are an important component of the immune microenvironment in the male reproductive system, involved in both physiological regulation and pathological processes via secretion of various bioactive substances. Modeling dysregulatio…
View article: Excess prenatal folic acid supplementation alters cortical gene expression networks and electrophysiology
Excess prenatal folic acid supplementation alters cortical gene expression networks and electrophysiology Open
Folate is crucial for various biological processes, with deficiencies during pregnancy being linked to increased risk for neural tube defects and neurodevelopmental disorders. As a proactive measure, folic acid fortification in foods has b…
View article: Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib Open
View article: Correction: Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes
Correction: Low Dose Iron Treatments Induce a DNA Damage Response in Human Endothelial Cells within Minutes Open
[This corrects the article DOI: 10.1371/journal.pone.0147990.].
View article: Supplementary Table 4 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
Supplementary Table 4 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer Open
Supplementary Table 4
View article: Supplementary Table S2 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
Supplementary Table S2 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer Open
Supplementary Table S2
View article: Data from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
Data from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer Open
Resistance to endocrine therapies (ET) is common in estrogen receptor (ER)–positive breast cancer, and most relapsed patients die with ET-resistant disease. Although genetic mutations provide explanations for some relapses, mechanisms of r…
View article: Supplementary Table S1 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
Supplementary Table S1 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer Open
Supplementary Table S1
View article: Supplementary Table 5 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
Supplementary Table 5 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer Open
Supplementary Table 5
View article: Supplementary Table 3 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
Supplementary Table 3 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer Open
Supplementary Table 3
View article: Supplementary Figures from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
Supplementary Figures from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer Open
Supplementary Figures
View article: Supplementary Table 6 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
Supplementary Table 6 from Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer Open
Supplementary Table 6
View article: Differentiation signals induce APOBEC3A expression via GRHL3 in squamous epithelia and squamous cell carcinoma
Differentiation signals induce APOBEC3A expression via GRHL3 in squamous epithelia and squamous cell carcinoma Open
Two APOBEC DNA cytosine deaminase enzymes, APOBEC3A and APOBEC3B, generate somatic mutations in cancer, thereby driving tumour development and drug resistance. Here, we used single-cell RNA sequencing to study APOBEC3A and APOBEC3B express…
View article: Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer
Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor–Targeted Therapy Drives Resistance in Breast Cancer Open
Resistance to endocrine therapies (ET) is common in estrogen receptor (ER)–positive breast cancer, and most relapsed patients die with ET-resistant disease. Although genetic mutations provide explanations for some relapses, mechanisms of r…
View article: Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer
Screening of a kinase inhibitor library identified novel targetable kinase pathways in triple-negative breast cancer Open
Triple-negative breast cancer (TNBC) is a highly invasive breast cancer subtype that is challenging to treat due to inherent heterogeneity and absence of estrogen, progesterone, and human epidermal growth factor 2 receptors. Kinase signali…
View article: Human-like<i>APOBEC3</i>gene expression and anti-viral responses following replacement of mouse<i>Apobec3</i>with the 7-gene human<i>APOBEC3</i>locus
Human-like<i>APOBEC3</i>gene expression and anti-viral responses following replacement of mouse<i>Apobec3</i>with the 7-gene human<i>APOBEC3</i>locus Open
The seven human APOBEC3 (hA3) genes encode polynucleotide cytidine deaminases that play vital roles in restricting replication of viruses and retrotransposons. However, off-target A3 deamination of the cellular genome is a major source of …
View article: Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer Open
PURPOSE Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer. METHODS A total of 156 …
View article: Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling
Proteomic profiling reveals that ESR1 mutations enhance cyclin-dependent kinase signaling Open
Three quarters of all breast cancers express the estrogen receptor (ER, ESR1 gene), which promotes tumor growth and constitutes a direct target for endocrine therapies. ESR1 mutations have been implicated in therapy resistance in metastati…
View article: High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design
High-resolution cryo-EM of the human CDK-activating kinase for structure-based drug design Open
View article: Differentiation signals induce APOBEC3A expression via GRHL3 in squamous epithelia and squamous cell carcinoma
Differentiation signals induce APOBEC3A expression via GRHL3 in squamous epithelia and squamous cell carcinoma Open
View article: Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer
Correction: The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer Open
View article: Selective inhibition of CDK9 in triple negative breast cancer
Selective inhibition of CDK9 in triple negative breast cancer Open
Targeted therapy for triple-negative breast cancers (TNBC) remains a clinical challenge due to tumour heterogeneity. Since TNBC have key features of transcriptionally addicted cancers, targeting transcription via regulators such as cyclin-…
View article: The Evolution of Affordable Technologies in Liquid Biopsy Diagnostics: The Key to Clinical Implementation
The Evolution of Affordable Technologies in Liquid Biopsy Diagnostics: The Key to Clinical Implementation Open
Cancer remains a leading cause of death worldwide, despite many advances in diagnosis and treatment. Precision medicine has been a key area of focus, with research providing insights and progress in helping to lower cancer mortality throug…
View article: Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition
Active growth signaling promotes senescence and cancer cell sensitivity to CDK7 inhibition Open
Tumor growth is driven by continued cellular growth and proliferation. Cyclin-dependent kinase 7's (CDK7) role in activating mitotic CDKs and global gene expression makes it therefore an attractive target for cancer therapies. However, wha…
View article: Deciphering Mutational Signature Dynamics in Hormone-Sensitive Breast Cancer During Treatment Adaptation.
Deciphering Mutational Signature Dynamics in Hormone-Sensitive Breast Cancer During Treatment Adaptation. Open
The DNA accumulates somatic changes before and after tumor initiation. These changes have been classified into mutational signatures (1) but only recently have studies begun to experimentally validate and functionally dissect these signatu…